CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses:
Research and development	$ 21,662	$ 11,185
General and administrative	15,820	7,528
Alvaxa IPR&D		738
Total operating expenses	37,482	19,451
Loss from operations	(37,482)	(19,451)
Other income (expense):
Interest income	800
Interest expense, including $0 and $645 with related parties in 2021 and 2020, respectively	(670)	(1,689)
Fair value adjustments on embedded debt derivatives, including $0 and $575 with related parties in 2021 and 2020, respectively		995
Loss on fixed asset disposition	(9)
Gain on debt extinguishment	567	45
Net loss	(36,794)	(20,100)
Cumulative dividends on convertible preferred stock		(104)
Net loss attributable to common stockholders	$ (36,794)	$ (20,204)
Net loss per common share, basic and diluted	$ (1.33)	$ (12.53)
Weighted-average number of shares used in computing net loss per common share, basic and diluted	27,710,686	1,612,140
Comprehensive loss:
Net loss	$ (36,794)	$ (20,204)
Other comprehensive items:
Unrealized loss on marketable securities	(333)
Total other comprehensive loss	(333)
Total comprehensive loss	$ (37,127)	$ (20,204)